Intensity Therapeutics Inc (INTS) Stock Price, Quote & News

Company Profile

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Industry: Biotechnology

Sector: Healthcare

Phone: 203 221 7381

Fax: 203 557 3023

Website: www.intensitytherapeutics.com

Address:

1 Enterprise Drive, Suite 430, Shelton, United States

TNNSTrade Mar. 20 at 7:12 PM

$INTS Feels like a good time for a bit of news. Everyone will be looking for something positive, unaffected by the Middle East. 👀

1 · Reply

LaffertyDaniel32 Mar. 20 at 2:26 AM

$INTS idk why I didn’t sell at 8 and just break even. What an oversight!

0 · Reply

Tortrocket Mar. 19 at 10:02 PM

$INTS anyone heard of when the earning report comes out? I'm assuming it should be out before April

0 · Reply

joel12365 Mar. 17 at 8:31 PM

$INTS I’d be a buyer at $2 most certainly Valuation would be around 8 million market cap maybe less But I doubt

0 · Reply

Eric1072 Mar. 16 at 3:03 PM

$INTS I'll buy back in when it hits $2

0 · Reply

MoneyClaw Mar. 16 at 2:18 PM

$INTS i am guessing dilution will hit this stock in the next few weeks. Good time to sell and buy back under 2 dollars.

1 · Reply

TNNSTrade Mar. 13 at 7:33 PM

$INTS My guess is we will hear news about the capital raise soon. The goal is restarting the other trial in Q2. So that would mean it's time to raise. Let's do this, and start moving towards the future!

0 · Reply

Ric_Flare Mar. 13 at 1:28 PM

$INTS I just don't really the understand the bear case for this stock. The expensive part of developing new drugs is the development part. That part is done and the trial data has been great so far. On paper they have plenty of cash and very little debt. What am I missing?

3 · Reply

TNNSTrade Mar. 12 at 2:44 PM

$INTS Well, we know what is next. Capital raise or partnership. Hoping for partnership with the strong early results. Will have to wait and see. The good thing, is the results are very strong, as expected. Life changing technology for many. Let's get this thing in some serious trials, and then to the people who are in need.

0 · Reply

LaffertyDaniel32 Mar. 12 at 1:55 PM

$INTS Another long winter ahead..when would the next read out be?

0 · Reply

Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause

Mar 12, 2026, 7:30 AM EDT - 9 days ago

Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study

Mar 6, 2026, 7:47 AM EST - 15 days ago

Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Feb 13, 2026, 8:58 AM EST - 5 weeks ago

Intensity Therapeutics Announces Reverse Stock Split

Jan 13, 2026, 7:47 AM EST - 2 months ago

Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities

Dec 11, 2025, 7:47 AM EST - 3 months ago

Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium

Dec 5, 2025, 7:30 AM EST - 3 months ago

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Dec 4, 2025, 7:47 AM EST - 3 months ago

Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium

Nov 6, 2025, 4:02 PM EST - 4 months ago

Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 31, 2025, 8:00 AM EDT - 5 months ago

Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock

$Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal$

Oct 30, 2025, 7:30 AM EDT - 5 months ago

Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal

Sep 10, 2025, 7:47 AM EDT - 6 months ago

Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

Sep 2, 2025, 7:47 AM EDT - 7 months ago

Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 7:47 AM EDT - 7 months ago

Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Aug 7, 2025, 4:06 PM EDT - 8 months ago

Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 4, 2025, 7:47 AM EDT - 8 months ago

Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025

Jun 30, 2025, 8:00 AM EDT - 9 months ago

Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)

Jun 11, 2025, 11:46 PM EDT - 10 months ago

Intensity Therapeutics, Inc. Announces Pricing of Public Offering

Jun 11, 2025, 4:06 PM EDT - 10 months ago

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Jun 11, 2025, 8:30 AM EDT - 10 months ago

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study

May 29, 2025, 8:00 AM EDT - 10 months ago

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 28, 2025, 8:00 AM EDT - 10 months ago

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

May 13, 2025, 4:06 PM EDT - 11 months ago

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 8:00 AM EDT - 11 months ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

Apr 25, 2025, 8:00 AM EDT - 11 months ago

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

Mar 13, 2025, 4:07 PM EDT - 1 year ago

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Jan 28, 2025, 8:00 AM EST - 1 year ago

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Jan 10, 2025, 8:00 AM EST - 1 year ago

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Dec 12, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Nov 21, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Nov 18, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Nov 13, 2024, 4:06 PM EST - 1 year ago

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 8, 2024, 8:01 AM EST - 1 year ago

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

Oct 31, 2024, 9:00 AM EDT - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:19 PM EDT - 1 year ago

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 9, 2024, 8:01 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

May 15, 2024, 8:01 AM EDT - 2 years ago

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

May 10, 2024, 8:01 AM EDT - 2 years ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

May 9, 2024, 4:08 PM EDT - 2 years ago

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 2, 2024, 8:01 AM EDT - 2 years ago

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

Mar 14, 2024, 4:09 PM EDT - 2 years ago

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 14, 2024, 8:00 AM EDT - 2 years ago

Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024

Feb 21, 2024, 8:01 AM EST - 2 years ago

Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference

Jan 3, 2024, 8:01 AM EST - 2 years ago

Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

Dec 12, 2023, 8:01 AM EST - 2 years ago

Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

Dec 8, 2023, 8:30 AM EST - 2 years ago

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

Dec 1, 2023, 8:01 AM EST - 2 years ago

Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium

Nov 13, 2023, 8:01 AM EST - 2 years ago

Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

$Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023$

Nov 2, 2023, 7:01 AM EDT - 2 years ago

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023

TNNSTrade Mar. 20 at 7:12 PM

$INTS Feels like a good time for a bit of news. Everyone will be looking for something positive, unaffected by the Middle East. 👀

1 · Reply

LaffertyDaniel32 Mar. 20 at 2:26 AM

$INTS idk why I didn’t sell at 8 and just break even. What an oversight!

0 · Reply

Tortrocket Mar. 19 at 10:02 PM

$INTS anyone heard of when the earning report comes out? I'm assuming it should be out before April

0 · Reply

joel12365 Mar. 17 at 8:31 PM

$INTS I’d be a buyer at $2 most certainly Valuation would be around 8 million market cap maybe less But I doubt

0 · Reply

Eric1072 Mar. 16 at 3:03 PM

$INTS I'll buy back in when it hits $2

0 · Reply

MoneyClaw Mar. 16 at 2:18 PM

$INTS i am guessing dilution will hit this stock in the next few weeks. Good time to sell and buy back under 2 dollars.

1 · Reply

TNNSTrade Mar. 13 at 7:33 PM

0 · Reply

Ric_Flare Mar. 13 at 1:28 PM

3 · Reply

TNNSTrade Mar. 12 at 2:44 PM

0 · Reply

LaffertyDaniel32 Mar. 12 at 1:55 PM

$INTS Another long winter ahead..when would the next read out be?

0 · Reply

OpenOutcrier Mar. 12 at 12:34 PM

$INTS (+1.0% pre) Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study https://ooc.bz/l/96443

0 · Reply

Pettechfl Mar. 12 at 12:13 PM

$INTS

0 · Reply

Pettechfl Mar. 12 at 12:11 PM

$INTS well glad to see that, guess time will tell if others realize what they have too.

0 · Reply

madape Mar. 12 at 11:49 AM

$INTS great news but we are in a cold market

0 · Reply

TA_Kongen Mar. 12 at 11:37 AM

$INTS Small watch here. Might give a spike.

1 · Reply

Jdhunter819 Mar. 12 at 11:36 AM

$INTS great news

0 · Reply

TNNSTrade Mar. 11 at 9:19 PM

$INTS there's an update to the investor presentation. Which moved study manuscript published out by a quarter.... But what in didn't do his move early data release or restart trials at all. Which means both should happen by the end of this quarter. News will be coming soon. 👀

0 · Reply

Danyola Mar. 11 at 5:09 PM

$INTS Q4 ER tomorrow after close

0 · Reply

TNNSTrade Mar. 11 at 2:00 PM

$INTS waiting for news can be like watching paint dry. 👀

0 · Reply

Ianwalsh15 Mar. 11 at 1:36 PM

$INTS

0 · Reply

Tortrocket Mar. 10 at 6:39 PM

$INTS are people accumulating this shares on this or just sitting on what they already got? Just asking for curiosity

2 · Reply

joel12365 Mar. 10 at 1:25 PM

$INTS May god bless us with a an amazing week. Lots of progress And lots of hope. Amen

1 · Reply

Market Cap	16.35M
Revenue (ttm)	0.00
Net Income (ttm)	-16.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	48,400
Avg Vol	58,773
Day's Range	N/A - N/A
Shares Out	2.52M
Stochastic %K	1%
Beta	3.62
Analysts	Sell
Price Target	$30.00